Intra-arterial Perfusion in Interventional Radiology

Sponsor
Palo Alto Veterans Institute for Research (Other)
Overall Status
Recruiting
CT.gov ID
NCT05458791
Collaborator
Canon Medical Systems, USA (Industry)
20
1
18
1.1

Study Details

Study Description

Brief Summary

Patients are being asked to participate in a study to better determine blood flow going to tumors in the liver. They will undergo an embolization procedure in interventional radiology where the goal is to provide treatment directly into the liver tumor. These treatments are delivered into the blood vessels feeding the tumors. Improving these treatments relies on better understanding the blood flow into the tumor. By understanding how much blood flows into the tumors, the goal is to make sure there is the best chance of killing the tumor. The investigators are attempting to use a special type of CT scan during the procedure to determine the blood flow to the tumors.

Condition or Disease Intervention/Treatment Phase
  • Device: Intra-arterial Perfusion

Detailed Description

Accurate liver imaging is critically important for the appropriate management of hepatocellular carcinoma (HCC) patients. The unique capability of the 4 dimensional (4D) CT system that combines CT and vascular imaging in real time has the great potential to provide physiologic and functional information to the operators to help guide therapy decisions during interventional procedures. However, the workflow, protocols and parameters have not been studied and optimized to support the use of perfusion techniques during interventional procedures. Efforts to reduce contrast and radiation doses associated with perfusion imaging to as low as reasonably achievable (ALARA) are also important steps to ensure patient safety while generating clinically meaningful images. Reducing radiation doses may be achieved by adjusting scan parameters, then applying reconstruction techniques to improve the image quality. The new generation of reconstruction algorithms, such as Model-Based iterative reconstruction, or deep-learning reconstruction algorithms (e.g. AiCE), simultaneously improve noise (lower dose) and enhances low contrast characteristics (less contrast). This pilot study aims to demonstrate the use of 4D CT system to acquire liver perfusion information to support the interventional procedure, and to derive as low as reasonably achievable (ALARA) dose levels and examine the robustness of reconstruction algorithms that generate clinically meaningful perfusion maps.

The study will investigate the impact of different dose levels, and the robustness of reconstruction algorithms on CT perfusion maps. A successful study could allow for dissemination of these methods for use to the wider physician audience with an optimum ALARA dose levels. Furthermore, the potential knowledge gained from this study will further educate the medical community about the potential benefits of 4D CT intra-arterial CT perfusion as an adjunct imaging technique and may steer the direction for future larger scale trials and studies.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Application of Intra-arterial CT Perfusion During Interventional Radiology
Actual Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Standard Dose Intra-arterial Perfusion

All patients will undergo standard of care interventional treatment for liver cancer. The procedure will take place utilizing fluoroscopic and CT guidance. During their procedure, patients will have intra-arterial CT perfusion maps derived of the liver including the region of the tumor. (n=10)

Device: Intra-arterial Perfusion
All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.

Low Dose Intra-arterial Perfusion

Investigate the impacts on contrast and radiation doses and the robustness of reconstruction algorithms on intra-arterial CT perfusion using a lower radiation dose technique. (N=10)

Device: Intra-arterial Perfusion
All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.

Outcome Measures

Primary Outcome Measures

  1. Quantification of Parameters for Intra-arterial Perfusion [1 Day to 1 year]

    Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.

Secondary Outcome Measures

  1. Impact of low dose radiation technique on intra-arterial perfusion parameters [1 Day to 1 Year]

    Evaluating low dose radiation on perfusion parameters

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age > or = 18 years

  2. primary or secondary liver tumor(s)

  3. Trans-arterial chemoembolization (TACE) or trans-catheter radio embolization (TARE) approved by multidisciplinary tumor board

  4. Tumor in an area without prior surgical or ablative therapy

  5. At least 1 tumor greater than 1.5 cm in greatest diameter

Exclusion Criteria:
  1. Not eligible for TACE procedure.

  2. Same additional exclusion criteria as aim 1

  3. Any residual ethiodized oil accumulation in the liver

  4. No prior IA treatment in the last year

Contacts and Locations

Locations

Site City State Country Postal Code
1 VA Palo Alto Health Care System Palo Alto California United States 94304

Sponsors and Collaborators

  • Palo Alto Veterans Institute for Research
  • Canon Medical Systems, USA

Investigators

  • Principal Investigator: Rajesh P Shah, MD, VA Palo Alto Health Care System - Interventional Radiology

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Palo Alto Veterans Institute for Research
ClinicalTrials.gov Identifier:
NCT05458791
Other Study ID Numbers:
  • SHA0010
First Posted:
Jul 14, 2022
Last Update Posted:
Jul 19, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Palo Alto Veterans Institute for Research
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 19, 2022